JBJulia Brandts

Julia Brandts

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julia Brandts has a total of 179 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of obicetrapib on glycaemia and new-onset diabetes: pooled analysis of BROADWAY/BROOKLYN and an updated meta-analysis of CETP inhibitor trials

    by Julia Brandts, Michael Szarek, Stephen J Nicholls, Fotios Barkas, Michael H Davidson, John J P Kastelein, Kausik K Ray

    Aims: New-onset diabetes (NoD) is a recognized effect of statin therapy potentially influencing acceptance of intensive LDL-C-lowering. In contrast, cholesteryl ester transfer protein (CETP) inhibition has been associated with lower NoD risk in earlier trials. We assessed the effect of the highly selective CETP inhibitor obicetrapib on glycaemia and NoD, contextualized within an updated meta-analysis of CETP inhibitor trials. Methods and results: Individual participant data from the phase 3 BROADWAY and BROOKLYN trials were pooled across 1700 participants without diabetes at baseline (899 normoglycaemic, 801 prediabetes; 38.8% women), randomized 2:1 to obicetrapib 10 mg or placebo for 52 weeks. The PRISMA-compliant, PROSPERO-registered systematic review identified six eligible trials reporting NoD. Pooled risk ratios were calculated using Mantel–Haenszel fixed-effect models, with pre-specified subgroup analyses by baseline glycaemic status and CETPi potency, and trial-level meta-regression. Obicetrapib did not increase HbA1c at week 52 vs. placebo (LSMD −0.02%, 95% CI −0.04 to 0.00). NoD occurred in 6.4% (obicetrapib) vs. 8.5% (placebo) (adjusted OR 0.69, 95% CI 0.47–1.03), directionally consistent across glycaemic strata. Restricted cubic spline analyses identified associations between HDL-C, apoA1 and Lp(a) changes and NoD risk, but not HbA1c change. In the meta-analysis, CETP inhibition was associated with a 16% lower risk of NoD (RR 0.84, 95% CI 0.79–0.90; I2 = 0%). Conclusion: Obicetrapib did not adversely affect glycaemia and was associated with a numerically lower risk of NoD, consistent with a CETP inhibitor class signal of a modestly lower risk. The PREVAIL trial will provide larger-longer evidence about obicetrapib and NoD.

  • Open Access

    Discovering heart failure patient pathways through event enrichment and abstraction

    by Anton Antonov, Harry H. Beyel, Marlo Verket, Christopher T. Schwanen, Viki Peeva, Marco Pegoraro, Julia Brandts, Dirk Müller-Wieland, Nikolaus Marx, Wil M.P. van der Aalst, et al.

  • Open Access

    Machine learning-driven prioritization of lipoprotein(a) testing: model development and validation

    by Christophe A T Stevens, Fotios Barkas, Julia Brandts, Sunganani Kwilasi, Kanika I Dharmayat, Amany Elshorbagy, Irene Karungi, Alireza Mahani, Mansour T A Sharabiani, Antonio J Vallejo-Vaz, et al.

    Aims: Elevated lipoprotein(a) [Lp(a)] is a common risk factor for cardiovascular disease affecting ∼1.4 billion people globally, with novel treatments under development. Guidelines recommend one-lifetime measurement, yet <1% are tested. Population-wide screening faces cost and implementation challenges. We developed a machine learning (ML) model to help prioritize patients for Lp(a) testing. Methods and results: Ethnicity-calibrated ML models were developed to identify individuals with elevated Lp(a) in the UK Biobank. Participants ≥37 years old (n = 438 579) were split into feature importance/selection (20%), derivation (60%), and validation (20%) datasets. Performances across risk-enhancing Lp(a) thresholds recommended by clinical guidelines (90, 125, 430 nmol/L) or entry criteria for ongoing Lp(a)-lowering trials (150, 175, 200 nmol/L) were evaluated. External validation was conducted in NHANES III. Screening 1 million people using a universal approach would identify 222 717 cases above 90 nmol/L and 1950 above 430 nmol/L. In contrast, applying ML-targeted testing using the same number of tests would identify 280 899 (+26%; 95% CI: 20–28%) and 6881 (+253%; 95% CI: 192–310%) cases, respectively. At the thresholds of 125, 150, 175, and 200 nmol/L, yield increases were 38% (95% CI: 35–40%), 51% (95% CI: 47–54%), 59% (95% CI: 55–63%), and 66% (95% CI: 61–71%). Across thresholds 90–430 nmol/L, ML-targeted testing (number needed to screen 3.6–145, AUC 0.61–0.84) required 21–72% fewer tests to identify 1 million cases. NHANES III validation demonstrated similar performance. Top 4 predictors included age, height (proxy for sex), total cholesterol, and statin use. Conclusion: An ML-guided approach to prioritize testing for elevated Lp(a) would require fewer tests to identify those above risk-enhancing thresholds or potentially eligible for emerging therapies, offering a scalable interim compromise between the low current testing rates and universal screening aspirations.


  • Open Access

    Effects of coaching with data management system intervention or usual care on glycemic control in patients with type 2 diabetes: A multicentre, randomised controlled trial

    by Marlo Verket, Larissa F. Buitkamp, Niveditha Daneeza Dinesh Kanna, Andreas Thomas, Ralf Denger, Friedrich Petry, Oliver Schubert‐Olesen, Wolfgang Stütz, Jörg Simon, Monika Pihusch, et al.

    Aims: Integrating a diabetes management system (DMS) and personal coaching in patient care may reduce the burden of type 2 diabetes (T2DM) on patients and help address the multifaceted challenges associated with diabetes management. This study aims to assess the impact of the DMS with online coaching in patients with T2DM on changes in HbA1c levels, quality of life, and usability over 26 weeks. Materials and Methods: In a multicentre, randomised, controlled trial, adults with T2DM were randomised 1:1 to either 52 weeks of DMS with remote coaching or to usual care by their diabetologist. The DMS enabled a digital diary of blood pressure, blood glucose, and other health parameters, while coaching sessions included structured assessments of individual patient needs. The primary endpoint was changes in the HbA1c level from baseline to 26 weeks. Secondary endpoints included health‐related quality of life (SF‐12), diabetes‐related problems (PAID), and DMS usability (System Usability Scale) at 26‐week follow‐up. Results: One hundred and fourteen participants (49 females, 58 ± 11 years old [mean ± standard deviation], HbA1c: 8.3% ± 0.7%, body mass index [BMI]: 35.3 ± 7.9 kg/m 2 , diabetes duration: 13.6 ± 7.7 years) were randomised and completed baseline. Ninety participants (39 female, age: 58 ± 11 years old, HbA1c: 8.3% ± 0.7%, BMI: 35.2 ± 7.6 kg/m 2 , diabetes duration: 14 ± 8 years) completed 26‐week follow‐up. The HbA1c levels improved significantly in the intervention group in comparison to the control group (−0.9% ± 1.0% vs. −0.5% ± 1.0%, p = 0.044). No significant differences were observed in SF‐12 and PAID scores at 26‐week follow‐up. Thirty‐two of forty‐three participants who used DMS completed the SUS questionnaire with an average score of 55.4 ± 27.9. Conclusions: DMS with coaching improved glycaemic control compared to usual care in patients with T2DM at 26‐week follow‐up.

  • Progressive atherosclerotic cardiovascular disease associated with high lipoprotein(a) – the German experience with lipoprotein apheresis and future perspectives with lipoprotein(a) lowering drugs

    by Reinhard Klingel, Julia Brandts, Andreas Heibges, Cordula Fassbender

    Lipoprotein(a) (Lp(a)) exhibits proinflammatory and proatherogenic properties. Evidence from prospective epidemiological studies, as well as Mendelian randomization studies, reveals an independent and causal association between elevated Lp(a) concentrations and atherosclerotic cardiovascular disease (ASCVD). Lipoprotein apheresis (LA) effectively lowers atherogenic lipoproteins when medication is insufficient. Since 2008, LA reimbursement for patients with high Lp(a) (> 60 mg/dL) and progressive ASCVD has been approved in Germany. To justify this policy, German authorities required prospective data, leading to the conduct of the Pro(a)LiFe study and establishment of the German Lipoprotein Apheresis Registry (GLAR). The Pro(a)LiFe study enrolled 170 patients with high Lp(a) and progressive ASCVD to evaluate LA’s long-term effect on cardiovascular event rates. Patients were investigated for 5 years before initiation of regular LA, then up to 12 years afterwards. Results showed a significant decline in mean annual cardiovascular events per patient from 0.27 (±0.25) in the 5 years before LA to 0.06 (±0.08) over the following 12 years (p < 0.001). Compared to a matched UK Biobank cohort, ASCVD event rates were higher before LA began and significantly lower afterwards. The results confirm that long-term treatment with LA is associated with low incidence of cardiovascular events in patients with high Lp(a) sustained over 12 years. Combining Lp(a) testing with LA has meaningfully reduced ASCVD events. Until Lp(a)-specific drugs receive regulatory approval, LA remains a viable treatment for selected high-risk patients. It will be important to assess whether results with novel pharmaceutical agents apply to the peculiar high-risk patients with high Lp(a) and progressive ASCVD.

  • Open Access

    Optimizing lipid-lowering therapy for acute coronary syndrome using a decision support system: insights from a cluster randomized trial

    by Christophe A T Stevens, Jessica Smith, Julia Brandts, Fotios Barkas, Maria Moreno Morales, Leila Janani, Gaia Kiru, Nandita Kaza, Victoria Cornelius, Neil R Poulter, et al.

    Aims: Lipid-lowering therapy (LLT) after acute coronary syndrome (ACS) typically follows stepwise intensification, delaying use of combination therapies and low-density lipoprotein cholesterol (LDL-C) goal attainment. We assessed whether access to a decision support system (DSS) altered the intensity of LLT prescribing vs. standard-of-care (SoC). Methods and results: Pragmatic, multinational, parallel 1:1 cluster-randomized controlled trial of ACS patients comparing mandatory access to a DSS (providing estimates of cardiovascular events and benefits from different LLT scenarios) to SoC. The primary endpoint was the proportion receiving intensified monotherapy or initiated/escalated combination LLT by Week 16 compared to pre-admission LLT; secondary endpoints included individual components of the primary endpoint, proportions at goal (LDL-C < 1.4 mmol/L), and timing of LLT escalations. 42 sites from UK, Italy, and Spain were randomized, enrolling 1139 participants, 79% male, median age 62 years (IQR: 55, 69), 84% without prior CVD, 69% LLT-naïve at admission, and median admission LDL-C 3.0 mmol/L (IQR: 2.46, 3.75). The primary endpoint was met in 71.7% (DSS) vs. 65.7% (SoC) and risk ratio (RR) 1.11 (95%CI:0.92–1.33, P = 0.29). Intensification of monotherapy occurred in 9.0% vs. 13.1% (RR: 0.68, 95%CI: 0.46–1.00), combination LLT in 61.6% vs. 50.6% (RR: 1.35, 95%CI: 0.93–1.98). LDL-C goal achievement was 54.8% vs. 50.3% (RR 1.06, 95%CI: 0.88–1.28), with LLT escalation before discharge in 64.8% vs. 60.7%. Conclusion: Access to a DSS, in hospitals managing ACS, did not improve LLT intensification within 16 weeks or LDL-C goal attainment but revealed a favourable trend towards earlier combination LLT use, which merits larger, longer studies in other settings.


  • Open Access

    International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE study

    by Julia Brandts, Fotios Barkas, Dirk De Bacquer, Catriona Jennings, Guy G De Backer, Kornelia Kotseva, Lars Ryden, Gregory Y H Lip, Iris Erlund, Sandra Ganly, et al.

    Aims: To quantify international variations in lipid-lowering therapies (LLT) use among patients with coronary heart disease (CHD) and attainment of European guideline-recommended lipid goals. Methods and results: INTERASPIRE is an observational study (2020–23) covering 14 countries from all WHO regions. Patients (18–79 years) hospitalized in the preceding 6–36 months with CHD were invited for standardized interviews and examination, with central laboratory analyses for low-density lipoprotein cholesterol (LDL-C), non-HDL-C, and apolipoprotein B (apoB). Valid lipid data meeting quality control standards were available from 13 countries. Lipid goals followed the 2019 guidelines of the European Atherosclerosis Society and the European Society of Cardiology: LDL-C < 1.4 mmol/L, non-HDL-C < 2.2 mmol/L, and apoB <65 mg/dL. Among 4061 patients (78.8% male, mean age 60.3 years), between index event and interview, 66.3% had no change in treatment intensity. LLT use at interview was largely statin monotherapy: 49.6% high-intensity (inter-country range 5.3%–77.3%) and 24.1% low/moderate-intensity (inter-country range 5.1%–70.1%). Otherwise, 12.2% (inter-country range 0.2%–41.1%) were on combination therapy, and 12.7% on no LLT (inter-country range 3.5%–36.7%). Goal attainment for LDL-C was 17.5%. Corresponding non-HDL-C and apoB goals were achieved by 29.9% and 29.2%, respectively. Higher-income countries (defined by the World Bank’s 2024–25 classification of income levels) did better in goal attainment than lower-middle-income countries. Conclusion: In this international study, contemporary lipid goals were not achieved in most CHD patients, with lower-middle-income countries having the worst goal attainment. Contributory factors include absence of any LLT use, low use of combinations and a failure to up-titrate LLT to achieve guideline targets.


  • Open Access

    Congestion assessment using a self-supervised contrastive learning-derived risk index in patients with congestive heart failure (CONAN): protocol and design of a prospective cohort study

    by Bojan Hartmann, Niels-Ulrik Hartmann, Julia Brandts, Marlo Verket, Nikolaus Marx, Niveditha Dinesh, Lisa Schuetze, Anna Emilia Pape, Dirk Müller-Wieland, Markus Kollmann, et al.

    Aims: Recurrent congestive episodes are a primary cause of hospitalizations in patients with heart failure. Hitherto, outpatient management adopts a reactive approach, assessing patients clinically through frequent follow-up visits to detect congestion early. This study aims to assess the capabilities of a self-supervised contrastive learning-derived risk index to detect episodes of acute decompensated heart failure (ADHF) in patients using continuously recorded wearable time-series data. Methods and results: This is the protocol for a single-arm, prospective cohort pilot study that will include 290 patients with ADHF. Acute decompensated heart failure is diagnosed by clinical signs and symptoms, as well as additional diagnostics (e.g. NT-proBNP). Patients will receive standard-of-care treatment, supplemented by continuous wearable-based monitoring of vital signs and physical activity, and are followed for 90 days. During follow-up, study visits will be conducted and presentations without clinical ADHF will be referred to as ‘regular’ and data from these episodes will be presented to a deep neural network that is trained by a self-supervised contrastive learning objective to extract features from the time-series that are typical in regular periods. The model is used to calculate a risk index measuring the dissimilarity of observed features from those of regular periods. The primary outcome of this study will be the risk index’s accuracy in detecting episodes with ADHF. As secondary outcome data integrity and the score in the validated questionnaire System Usability Scale will be evaluated. Conclusion: Demonstrating reliable congestion detection through continuous monitoring with a wearable and self-supervised contrastive learning could assist in pre-emptive heart failure management in clinical care. Clinical trial registration: The study was registered in the German clinical trials register (DRKS00034502).